Ypsomed doubles profits and confirms outlook

Ad hoc announcement pursuant to Art. 53 LR

Burgdorf, 15.11.2023, 07:00 a.m. – Ypsomed (SIX: YPSN) continues its growth trend and achieved consolidated sales of CHF 255.4 million in the first six months of the 2023/24 financial year (previous year: CHF 244.2 million). 

Read more...

Samuel Künzli succeeds Niklaus Ramseier as CFO and member of the Executive Board

Ad hoc announcement pursuant to Art. 53 LR

Burgdorf, 29.09.2023, 7:00 a.m. – Ypsomed (SIX: YPSN) announces a change in its Executive Board. After more than twenty years, Niklaus Ramseier will hand over his functions as Chief Financial Officer (CFO) on 31 March 2024 and will continue to be available to the company for strategic projects. His successor is Samuel Künzli, who will start his position as CFO on 01 April 2024.

Read more...

Ypsomed concludes a long-term supply agreement for large quantities of autoinjectors

Ad hoc announcement pursuant to Art. 53 LR

Burgdorf – Ypsomed (SIX: YPSN) has concluded a long-term supply agreement with Novo Nordisk for large quantities of autoinjectors. The autoinjectors will be used to administer drugs for the self-treatment in various metabolic indications. Ypsomed is in the process of substantially increasing its annual manufacturing capacity in several steps until 2031.

Read more...

Ypsomed doubles profits and confirms outlook

Ad hoc announcement pursuant to Art. 53 LR

Burgdorf – Ypsomed (SIX: YPSN) continues its growth trend and achieved consolidated sales of CHF 497.5 million in the 2022/23 financial year (previous year: CHF 464.8 million). Adjusted for the effect of the divestment of DiaExpert, continuing business demonstrated growth of 16%, or approximately 19% currency adjusted. The reported growth in turnover corresponds to a growth of 7% compared to the previous year. At constant exchange rates compared to the previous year, this would have represented an increase of around 10%. With this growth, the company has significantly increased both its operating profit (EBIT) from CHF 28.6 million to CHF 60.6 million as well as more than doubled its net profits to CHF 51.3 million (previous year CHF 23.1 million). Ypsomed confirms the outlook for the 2023/24 financial year.

Read more...

Burgdorf – Eli Lilly and Company (NYSE: LLY) has decided to fully focus on its successful drug portfolio. Therefore, Lilly decided to stop the joint project with Ypsomed (SIX: YPSN) to enter the US insulin pump market in 2026. Ypsomed plans to submit its YpsoPump system to the FDA in the second half of 2023 according to plan, and subsequently commercialize the system with a new partner.

Read more...